$10.52
2.33% today
Nasdaq, Aug 12, 04:50 pm CET
ISIN
US71722W1071
Symbol
PHAT

Phathom Pharmaceuticals Inc Stock price

$10.28
+1.10 11.98% 1M
+4.89 90.72% 6M
+2.16 26.60% YTD
-1.75 14.55% 1Y
+1.14 12.47% 3Y
-26.73 72.22% 5Y
-14.32 58.21% 10Y
-14.32 58.21% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.54 5.54%
ISIN
US71722W1071
Symbol
PHAT
Industry

Key metrics

Basic
Market capitalization
$729.3m
Enterprise Value
$1.1b
Net debt
$352.0m
Cash
$212.3m
Shares outstanding
69.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.9 | 4.5
EV/Sales
13.2 | 6.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-67.0%
Return on Equity
131.8%
ROCE
-130.1%
ROIC
-
Debt/Equity
-1.7
Financials (TTM | estimate)
Revenue
$81.9m | $162.7m
EBITDA
$-285.6m | $-168.9m
EBIT
$-286.4m | $-194.7m
Net Income
$-345.8m | $-245.7m
Free Cash Flow
$-282.8m
Growth (TTM | estimate)
Revenue
3,060.6% | 194.4%
EBITDA
-38.3% | 39.0%
EBIT
-38.2% | 29.8%
Net Income
-40.2% | 26.5%
Free Cash Flow
-67.9%
Margin (TTM | estimate)
Gross
86.2%
EBITDA
-348.9% | -103.8%
EBIT
-349.8%
Net
-422.4% | -151.0%
Free Cash Flow
-345.5%
More
EPS
$-4.8
FCF per Share
$-4.1
Short interest
23.2%
Employees
427
Rev per Employee
$130.0k
Show more

Is Phathom Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Phathom Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

Buy
87%
Hold
13%

Financial data from Phathom Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
82 82
3,061% 3,061%
100%
- Direct Costs 11 11
1,810% 1,810%
14%
71 71
3,430% 3,430%
86%
- Selling and Administrative Expenses 323 323
100% 100%
395%
- Research and Development Expense 34 34
29% 29%
41%
-286 -286
38% 38%
-349%
- Depreciation and Amortization 0.76 0.76
19% 19%
1%
EBIT (Operating Income) EBIT -286 -286
38% 38%
-350%
Net Profit -346 -346
40% 40%
-422%

In millions USD.

Don't miss a Thing! We will send you all news about Phathom Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Phathom Pharmaceuticals Inc Stock News

Neutral
Seeking Alpha
5 days ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Eric Sciorilli - Corporate Participant Robert Breedlove - VP of Finance & Principal Accounting Officer Steven L. Basta - CEO, President & Director Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Robert S...
Positive
The Motley Fool
5 days ago
Phathom (PHAT) Q2 Revenue Jumps 441%
Neutral
GlobeNewsWire
5 days ago
FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates.
More Phathom Pharmaceuticals Inc News

Company Profile

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Head office United States
CEO Steven Basta
Employees 427
Founded 2018
Website www.phathompharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today